Trident Lifeline

Trident Lifeline EBITDA per Share

Delisted·Sep 16, 2026

The EBITDA per Share of Trident Lifeline (543616.BO) as of Nov 9, 2026 is 12.92 INR. In the previous year, EBITDA per Share was 7.12 INR — a change of 81.45% (higher).

EBITDA per Share

12.92INR

YoY

81.45%

Last updated:

EBITDA per Share of Trident Lifeline is 2025 12.92 INR. EBITDA per Share of Trident Lifeline was 2024 7.12 INR. It decreases by 81.45% higher compared to the previous year.

The Trident Lifeline EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
1.08 INR
Jan 1, 2022
2.36 INR
Jan 1, 2023
5.44 INR
Jan 1, 2024
7.12 INR
Jan 1, 2025
12.92 INR
The Trident Lifeline EBITDA per Share history
YEAREBITDA per ShareYoY
12.92INR+81.45%
7.12INR+31.03%
5.44INR+130.79%
2.36INR+117.86%
1.08INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trident Lifeline Stock analysis

What does Trident Lifeline do? Trident Lifeline Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across seven geographical segments including India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, and Rest of World. The company produces a diverse range of pharmaceutical formulations such as capsules, tablets, liquid ointments, gels, mouthwashes, and toothpaste under contract manufacturing on loan license. Its product portfolio features drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive, Anti Lipidemic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Non-Steroidal Anti-Inflammatory Drug (NSAIDS). The primary buyers are healthcare providers and consumers in the pharmaceutical market, with a focus on both domestic and international markets. The company's revenue streams are derived from the sale of its extensive product range, which includes both prescription and over-the-counter medications. By operating through multiple geographical segments, Trident Lifeline Ltd. caters to a broad customer base across different regions, ensuring consistent demand for its pharmaceutical formulations. The contract manufacturing model under loan license allows the company to leverage partnerships without significant capital investment, optimizing production costs and scalability. Trident Lifeline Ltd. targets healthcare providers and consumers seeking affordable pharmaceutical solutions, particularly in emerging markets. Its product offerings address a wide spectrum of health needs, from common ailments like diarrhea and fungal infections to chronic conditions such as diabetes and hypertension. This strategic focus on diverse drug categories ensures steady demand across its operational segments, supporting sustainable revenue growth. Trident Lifeline is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trident Lifeline stock

EBITDA per Share of Trident Lifeline is 12.92 INR in 2025.

EBITDA per Share of Trident Lifeline changed from 7.12 INR to 12.92 INR, representing a 81.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Trident Lifeline since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Trident Lifeline

All Key Metrics — Trident Lifeline